Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Malik Fady Ibraham, holds the title of EVP Research & Development at CYTOKINETICS INC.
On 2026-10-06, the insider transacted 7,000 shares.The shares were transacted at a weighted average price of $34.59 per share, resulting in a total market-relevant value of $242K.
Malik Fady Ibraham (EVP Research & Development) sold $242K of $CYTK
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.